Reply Doubles its AI-based International Competitions: Introducing the Reply AI Music Contest and Welcoming Back the Reply AI Film Festival
Reply, driven by its strong culture of innovation and its commitment to engaging younger generations in the use of new technology, is expanding its creative experimentation initiatives with the launch of the Reply AI Music Contest- an international competition dedicated to the use of Artificial Intelligence in live musical performances.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250402208295/en/
Reply, driven by its strong culture of innovation and its commitment to engaging younger generations in the use of new technology, is expanding its creative experimentation initiatives with the launch of the Reply AI Music Contest - an international competition dedicated to the use of Artificial Intelligence in live musical performances.
This music contest, organised in partnership with Kappa FuturFestival, one of Europe's most prestigious electronic music festivals, offers the finalists the unique opportunity to perform live on stage at the festival, which will take place in Turin from 4 to 6 July 2025. The competition's theme is 'Experience of a Beat', and it invites young artists to create immersive experiences by integrating AI into music, visual art, and audience interaction. The entries, which can be up to five minutes long, will be judged by a panel of DJs, AI artists, Reply technology experts, and media partners. The criteria of the judges will be based on the creativity, the integration of sound and visuals, and its live performance potential.
Along with this new initiative, Reply announces the launch of the second edition of the Reply AI Film Festival, the international competition dedicated to creatives, directors, and video makers interested in creating short films using AI tools. Participants will be able to use AI in various stages of production, including scripting, storyboarding, image and video creation, visual and sound effects, and much more.
Thanks to the collaboration with Mastercard, which is committed to connecting consumers with their passions and supporting emerging talent, the finalists will be invited to a premiere event hosted by Reply and Mastercard in Venice in September, where the three winning short films will be announced.
The year’s theme is "Generation of Emotions", celebrating the talents able to create cinematic experiences that evoke authentic emotions through the potential of AI. A distinguished jury of film, visual arts and AI experts will evaluate the submissions and select the ten best original works, each with a maximum length of 10 minutes.
This second edition introduces two special awards: the “Lexus Visionary Award”, which recognises the most visionary and innovative work - one that best integrates technology, design and future insight, embodying the values that have always guided Lexus's forward-thinking vision - and the “AI For Good Award”, in partnership with the International Telecommunication Union (ITU), which will be given to the best short film highlighting the United Nations Sustainable Development Goals (SDGs).
“As part of our initiatives to promote new technologies among younger generations, Reply continues to promote and foster its culture of innovation by offering new spaces for creative experimentation. The Reply AI Film Festival and the Reply AI Music Contest are unique opportunities to explore the potential of Artificial Intelligence as an ally of human creativity, demonstrating how the synergy between people and technology can open up new, more accessible scenarios for everyone with a spark of creativity,” commented Filippo Rizzante, CTO of Reply.
Creative talents from all over the world can participate in the Reply AI Music Contestand the Reply AI Film Festival by submitting their entries through the dedicated platforms — aimc.reply.comand aiff.reply.com — by June 1st, 2025.
These contests are part of Reply Challenges, a program of technological and creative competitions that reflect Reply’s commitment to developing innovative educational models to engage new generations. Today, the Reply Challenges community has more than 150,000 participants worldwide.
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in designing and implementing solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply supports major European industrial groups in the telecom and media, industry and services, banking and insurance and public sectors in defining and developing business models enabled by the new paradigms of AI, cloud computing, digital media and the internet of things. Reply's services include consulting, system integration and digital services. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402208295/en/
Contacts
Media Contact:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Irene Caia
i.caia@reply.com
Tel. +39 02 535761
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom